JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Brian Cheng maintains Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight and lowers the price target from $46 to $33.
JP Morgan analyst Brian Cheng maintains Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight and lowers the price target from $46 to $33.